Been digging into some old market data and came across something worth revisiting - 2015 was honestly one of the slowest years for IPOs in recent memory. Only 169 companies that went public in 2015, which sounds like a lot until you realize it was 40% fewer than the year before. The dollar value was even more brutal - dropped from $85 billion down to just $30 billion. Market sentiment had cooled off big time, and honestly, a lot of the hype stocks like Uber just decided to skip the whole public market thing and raise privately instead.

But here's the thing - even in a weak year, there were still massive winners and losers among the companies that went public in 2015. The winners were actually pretty interesting.

Speak Therapeutics absolutely crushed it, up 122% from its January debut by year-end. They were working on gene therapy for rare eye diseases, priced the offering at $23 (higher than expected), and just kept climbing. Then you had Seres Therapeutics, another biotech play that more than doubled after launching at $18. And Shake Shack - the burger chain everyone knows - hit the market at $21 and roughly doubled as well. These companies that went public in 2015 in the biotech and consumer space really captured investor imagination.

The losers, though? Rough. MaxPoint Interactive got absolutely destroyed, down 88% from its $11.50 opening price in March. Marketing tech company with decent sales growth, but the losses just kept mounting. Zosano Pharma was another bloodbath - their transdermal patch technology seemed promising at $11, but they killed a major partnership and discontinued a key drug program. Stock cratered 77%. Belloran Pharmaceuticals was similarly brutal, losing about 75% of its value after initial hype around their hypertension treatment fizzled.

What's wild is how predictable the pattern was - biotech startups absolutely dominated both the winners and losers lists. When you're betting on early-stage drug development, you're either going to win big or lose big. There's rarely a middle ground. The whole 2015 IPO class showed that market sentiment matters way more than the initial hype. Companies that could actually execute and show real progress kept climbing. Those that couldn't? They got punished hard.